Metabolism. 2026 Nov 14:156845. doi: 10.1016/j.metabol.2026.156845. Online ahead of print.
ABSTRACT
Endogenous hypercortisolism, namely Cushing's syndrome (CS) is a rare but severe endocrine disorder caused by chronic exposure to excess glucocorticoids and characterized by substantial morbidity and increased mortality. Persistent hypercortisolism profoundly affects multiple cardiovascular and metabolic pathways, leading to a broad spectrum of cardio-liver-metabolic complications including arterial hypertension, cardiac and vascular remodelling, thrombotic diathesis, hepatic steatosis, visceral obesity, impaired glucose metabolism, and dyslipidemia. These alterations arise from complex interactions between direct glucocorticoid effects on target tissues and indirect mechanisms, mainly involving insulin resistance, endothelial dysfunction, chronic inflammation, and altered lipid metabolism. The primary therapeutic objective in CS is the normalization of cortisol excess through surgery, radiotherapy, or medical therapy, namely pharmacological treatment. In recent years, the availability of medical drugs targeting pituitary ACTH secretion, adrenal steroidogenesis, or glucocorticoid receptor signalling has expanded therapeutic options for patients with CS, especially with persistent or recurrent disease. Beyond biochemical control of hypercortisolism, namely normalization of urinary free cortisol (UFC) (UFC ≤ upper limit of normal), accumulating evidence suggests that these treatments may improve several cardiometabolic manifestations associated with cortisol excess. However, although remission of hypercortisolism leads to significant clinical improvement, complete normalization of cardio-liver-metabolic alterations is not consistently achieved. Many patients continue to exhibit persistent cardiovascular and metabolic abnormalities even after long-term biochemical remission, highlighting the need for active long-term monitoring and multidisciplinary management to prevent disease progression and optimize long-term outcomes. This mini-review briefly outlines the pathogenesis of cardio-liver-metabolic dysfunctions and discusses the potential effects of currently available therapeutic strategies targeting hypercortisolism on these comorbidities.
PMID:43033903 | DOI:10.1016/j.metabol.2026.156845

